Search

Your search keyword '"Ferreira, Vanessa M."' showing total 388 results
Start Over Author "Ferreira, Vanessa M." Search Limiters Full Text

Refine your results

388 results on '"Ferreira, Vanessa M."'

1. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Author

Alparaque, Maricel, Anid, Liisa, Barnes, Eleanor, Benamore, Rachel, Bharti, Neha, Patel, Bhumika, Burns, Adrian, Byard, Nicholas, Conway, Oliver, Cooper, Cushla, Crowther, Charlotte, Dunachie, Susanna J, Johnstone, Trudi, Jose, Jyolsna, Luciw, Michael, Mujadidi, Yama, Nehiweze, Aiseosa, Nyamunda, Sibongile, Orobiyi-Rieba, Maria, Parvelikudy, Bindu, Platt, Abigail, Pswarayi, Dzikamayi, Quaddy, Jack, Samuel, Binnie Elizabeth, Sette, Alessandro, Sodipo, Victoria, Srijith, Preethu, Stone, Helen, Turner, Cheryl, Valmores, Mary Ann, Voaides, Alexandru, Vuddamalay, Gavindren, Jackson, Susan, Marshall, Julia L, Mawer, Andrew, Lopez-Ramon, Raquel, Harris, Stephanie A, Satti, Iman, Hughes, Eileen, Preston-Jones, Hannah, Cabrera Puig, Ingrid, Longet, Stephanie, Tipton, Tom, Laidlaw, Stephen, Doherty, Rebecca Powell, Morrison, Hazel, Mitchell, Robert, Tanner, Rachel, Ateere, Alberta, Stylianou, Elena, Wu, Meng-San, Fredsgaard-Jones, Timothy P W, Breuer, Judith, Rapeport, Garth, Ferreira, Vanessa M, Gleeson, Fergus, Pollard, Andrew J, Carroll, Miles, Catchpole, Andrew, Chiu, Christopher, and McShane, Helen

Published
2024
Full Text
View/download PDF

5. The Society for Cardiovascular Magnetic Resonance Registry at 150,000

Author

Tong, Matthew S., Slivnick, Jeremy A., Sharif, Behzad, Kim, Han W., Young, Alistair A., Sierra-Galan, Lilia M., Mukai, Kanae, Farzaneh-Far, Afshin, Al-Kindi, Sadeer, Chan, Angel T., Dibu, George, Elliott, Michael D., Ferreira, Vanessa M., Grizzard, John, Kelle, Sebastian, Lee, Simon, Malahfji, Maan, Petersen, Steffen E., Polsani, Venkateshwar, Toro-Salazar, Olga H., Shaikh, Kamran A., Shenoy, Chetan, Srichai, Monvadi B., Stojanovska, Jadranka, Tao, Qian, Wei, Janet, Weinsaft, Jonathan W., Wince, W. Benjamin, Chudgar, Priya D., Judd, Matthew, Judd, Robert M., Shah, Dipan J., and Simonetti, Orlando P.

Published
2024
Full Text
View/download PDF

8. Acute Response in the Noninfarcted Myocardium Predicts Long-Term Major Adverse Cardiac Events After STEMI

Author

Shanmuganathan, Mayooran, Masi, Ambra, Burrage, Matthew K., Kotronias, Rafail A., Borlotti, Alessandra, Scarsini, Roberto, Banerjee, Abhirup, Terentes-Printzios, Dimitrios, Zhang, Qiang, Hann, Evan, Tunnicliffe, Elizabeth, Lucking, Andrew, Langrish, Jeremy, Kharbanda, Rajesh, De Maria, Giovanni Luigi, Banning, Adrian P., Choudhury, Robin P., Channon, Keith M., Piechnik, Stefan K., and Ferreira, Vanessa M.

Published
2023
Full Text
View/download PDF

9. Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study

Author

Artico, Jessica, Shiwani, Hunain, Moon, James C., Gorecka, Miroslawa, McCann, Gerry P., Roditi, Giles, Morrow, Andrew, Mangion, Kenneth, Lukaschuk, Elena, Shanmuganathan, Mayooran, Miller, Christopher A., Chiribiri, Amedeo, Prasad, Sanjay K., Adam, Robert D., Singh, Trisha, Bucciarelli-Ducci, Chiara, Dawson, Dana, Knight, Daniel, Fontana, Marianna, Manisty, Charlotte, Treibel, Thomas A., Levelt, Eylem, Arnold, Ranjit, Macfarlane, Peter W., Young, Robin, McConnachie, Alex, Neubauer, Stefan, Piechnik, Stefan K., Davies, Rhodri H., Ferreira, Vanessa M., Dweck, Marc R., Berry, Colin, Greenwood, John P., Kelly, Bernard, Goreka, Miroslawa, Somers, Kathryn, Byrom-Goulthorp, Roo J., Anderson, Michelle, Britton, Laura, Richards, Fiona, Jones, Laura M., Moss, Alastair, Fisher, Jude, Wormleighton, Joanne, Parke, Kelly, Wright, Rachel, Yeo, Jian, Falconer, Judith, Harries, Valerie, Henderson, Paula, Newby, David, Popescu, Iulia, Zhang, Qiang, Raman, Betty, Channon, Keith, Krasopoulos, Catherine, Nunes, Claudia, Da Silva Rodrigues, Liliana, Nixon, Harriet, Panopoulou, Athanasia, Fletcher, Alison, Manley, Peter, Sykes, Robert, Fallon, Kirsty, Brown, Ammani, Kelly, Laura, McGinley, Christopher, Briscoe, Michael, Woodward, Rosemary, Hopkins, Tracey, McLennan, Evonne, Tynan, Nicola, Dymock, Laura, Swoboda, Peter, Wright, Judith, Exley, Donna, Steeds, Richard, Hutton, Kady, MacDonald, Sonia, Shetye, Abhishek, Orsborne, Christopher, Woodville-Jones, William, Ferguson, Susan, Bratis, Konstantinos, Fairbairn, Timothy, Sionas, Michail, Widdows, Peris, Gee Chew, Pei, Marsden, Christian, Collins, Tom, George, Linsha, Kearney, Lisa, Flett, Andrew, Smith, Simon, Zhenge, Alice, Harvey, Jake, Inacio, Liliana, Hanam-Penfold, Tomas, Gruner, Lucy, Razvi, Yousuf S.K., Crause, Jacolene, Davies, Nina M., Brown, James T., Chaco, Liza, Patel, Rishi, Kotecha, Tushar, Knight, Dan S., Green, Thomas, Ripley, David, Thompson, Maria, Cifra, Ugochi Akerele Elna, Alskaf, Ebraham, Crawley, Richard, Villa, Adriana, Nightingale, Angus K., Wright, Kim, Bonnick, Esther D., Hopkins, Emma, George, Jessy, Joseph, Linta, Cole, Graham, Vimalesvaran, Kavitha, Ali, Nadine, Carr, Caitlin R., Ross, Alexandra A.R., King, Clara, Farzad, Zohreh, Salmi, Sara A., Kirby, Kevin, McDiarmid, Adam, Stevenson, Hannah J., Matsvimbo, Pamela S., Joji, Lency, Fearby, Margaret, Brown, Benjamin, Bunce, Nicholas, Jennings, Robert, Sookhoo, Vennessa, Joshi, Shatabdi, Kanagala, Prathap, Fullalove, Sandra, Toohey, Catherine, Fenlon, Kate, Bellenger, Nicholas, He, Jingzhou, Statton, Sarah, Pamphilon, Nicola, Steele, Anna, Ball, Claire, McGahey, Ann, Balma, Silvia, Wilkes, Lynsey, Lewis, Katy, Walter, Michelle, Ionescu, Adrian, Ninan, Tishi, Richards, Suzanne, Williams, Marie, Alfakih, Khaled, Pilgrim, Samia, Joy, George, and Hussain, Ifza

Published
2023
Full Text
View/download PDF

10. Cardiovascular Magnetic Resonance for Patients With COVID-19

Author

Petersen, Steffen E., Friedrich, Matthias G., Leiner, Tim, Elias, Matthew D., Ferreira, Vanessa M., Fenski, Maximilian, Flamm, Scott D., Fogel, Mark, Garg, Ria, Halushka, Marc K., Hays, Allison G., Kawel-Boehm, Nadine, Kramer, Christopher M., Nagel, Eike, Ntusi, Ntobeko A.B., Ostenfeld, Ellen, Pennell, Dudley J., Raisi-Estabragh, Zahra, Reeder, Scott B., Rochitte, Carlos E., Starekova, Jitka, Suchá, Dominika, Tao, Qian, Schulz-Menger, Jeanette, and Bluemke, David A.

Published
2022
Full Text
View/download PDF

11. Symptom Persistence Despite Improvement in Cardiopulmonary Health – Insights from longitudinal CMR, CPET and lung function testing post-COVID-19

Author

Cassar, Mark Philip, Tunnicliffe, Elizabeth M., Petousi, Nayia, Lewandowski, Adam J., Xie, Cheng, Mahmod, Masliza, Samat, Azlan Helmy Abd, Evans, Rachael A., Brightling, Christopher E., Ho, Ling-Pei, Piechnik, Stefan K., Talbot, Nick P., Holdsworth, David, Ferreira, Vanessa M., Neubauer, Stefan, and Raman, Betty

Published
2021
Full Text
View/download PDF

12. Coronary Microvascular Dysfunction Assessed by Pressure Wire and CMR After STEMI Predicts Long-Term Outcomes

Author

Scarsini, Roberto, Shanmuganathan, Mayooran, De Maria, Giovanni Luigi, Borlotti, Alessandra, Kotronias, Rafail A., Burrage, Matthew K., Terentes-Printzios, Dimitrios, Langrish, Jeremy, Lucking, Andrew, Fahrni, Gregor, Cuculi, Florim, Ribichini, Flavio, Choudhury, Robin P., Kharbanda, Rajesh, Ferreira, Vanessa M., Channon, Keith M., and Banning, Adrian P.

Published
2021
Full Text
View/download PDF

13. Markers of Myocardial Damage Predict Mortality in Patients With Aortic Stenosis

Author

Kwak, Soongu, Everett, Russell J., Treibel, Thomas A., Yang, Seokhun, Hwang, Doyeon, Ko, Taehoon, Williams, Michelle C., Bing, Rong, Singh, Trisha, Joshi, Shruti, Lee, Heesun, Lee, Whal, Kim, Yong-Jin, Chin, Calvin W.L., Fukui, Miho, Al Musa, Tarique, Rigolli, Marzia, Singh, Anvesha, Tastet, Lionel, Dobson, Laura E., Wiesemann, Stephanie, Ferreira, Vanessa M., Captur, Gabriella, Lee, Sahmin, Schulz-Menger, Jeanette, Schelbert, Erik B., Clavel, Marie-Annick, Park, Sung-Ji, Rheude, Tobias, Hadamitzky, Martin, Gerber, Bernhard L., Newby, David E., Myerson, Saul G., Pibarot, Phillipe, Cavalcante, João L., McCann, Gerry P., Greenwood, John P., Moon, James C., Dweck, Marc R., and Lee, Seung-Pyo

Published
2021
Full Text
View/download PDF

14. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge

Author

Raman, Betty, Cassar, Mark Philip, Tunnicliffe, Elizabeth M., Filippini, Nicola, Griffanti, Ludovica, Alfaro-Almagro, Fidel, Okell, Thomas, Sheerin, Fintan, Xie, Cheng, Mahmod, Masliza, Mózes, Ferenc E., Lewandowski, Adam J., Ohuma, Eric O., Holdsworth, David, Lamlum, Hanan, Woodman, Myles J., Krasopoulos, Catherine, Mills, Rebecca, McConnell, Flora A. Kennedy, Wang, Chaoyue, Arthofer, Christoph, Lange, Frederik J., Andersson, Jesper, Jenkinson, Mark, Antoniades, Charalambos, Channon, Keith M., Shanmuganathan, Mayooran, Ferreira, Vanessa M., Piechnik, Stefan K., Klenerman, Paul, Brightling, Christopher, Talbot, Nick P., Petousi, Nayia, Rahman, Najib M., Ho, Ling-Pei, Saunders, Kate, Geddes, John R., Harrison, Paul J., Pattinson, Kyle, Rowland, Matthew J., Angus, Brian J., Gleeson, Fergus, Pavlides, Michael, Koychev, Ivan, Miller, Karla L., Mackay, Clare, Jezzard, Peter, Smith, Stephen M., and Neubauer, Stefan

Published
2021
Full Text
View/download PDF

17. Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: protocol design of COVID-HEART—a UK, multicentre, observational study

Author

Gorecka, Miroslawa, McCann, Gerry P., Berry, Colin, Ferreira, Vanessa M., Moon, James C., Miller, Christopher A., Chiribiri, Amedeo, Prasad, Sanjay, Dweck, Marc R., Bucciarelli-Ducci, Chiara, Dawson, Dana, Fontana, Marianna, Macfarlane, Peter W., McConnachie, Alex, Neubauer, Stefan, and Greenwood, John P.

Published
2021
Full Text
View/download PDF

20. Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR)

Author

Ordovas, Karen G., Baldassarre, Lauren A., Bucciarelli-Ducci, Chiara, Carr, James, Fernandes, Juliano Lara, Ferreira, Vanessa M., Frank, Luba, Mavrogeni, Sophie, Ntusi, Ntobeko, Ostenfeld, Ellen, Parwani, Purvi, Pepe, Alessia, Raman, Subha V., Sakuma, Hajime, Schulz-Menger, Jeanette, Sierra-Galan, Lilia M., Valente, Anne Marie, and Srichai, Monvadi B.

Published
2021
Full Text
View/download PDF

23. Misclassification of females and males in cardiovascular magnetic resonance parametric mapping: the importance of sex-specific normal ranges for diagnosis of health vs. disease.

Author

Thomas, Katharine E, Lukaschuk, Elena, Shanmuganathan, Mayooran, Kitt, Jamie A, Popescu, Iulia A, Neubauer, Stefan, Piechnik, Stefan K, and Ferreira, Vanessa M

Subjects
MYOCARDIUM physiology, REFERENCE values, AGE distribution, MAGNETIC resonance imaging, SIMULATION methods in education, SEX distribution, HEART beat, DESCRIPTIVE statistics, RESEARCH funding, DIAGNOSTIC errors
Abstract

Aims Cardiovascular magnetic resonance parametric mapping enables non-invasive quantitative myocardial tissue characterization. Human myocardium has normal ranges of T1 and T2 values, deviation from which may indicate disease or change in physiology. Normal myocardial T1 and T2 values are affected by biological sex. Consequently, normal ranges created with insufficient numbers of each sex may result in sampling biases, misclassification of healthy values vs. disease, and even misdiagnoses. In this study, we investigated the impact of using male normal ranges for classifying female cases as normal or abnormal (and vice versa). Methods and results One hundred and forty-two healthy volunteers (male and female) were scanned on two Siemens 3T MR systems, providing averaged global myocardial T1 and T2 values on a per-subject basis. The Monte Carlo method was used to generate simulated normal ranges from these values to estimate the statistical accuracy of classifying healthy female or male cases correctly as 'normal' when using sex-specific vs. mixed-sex normal ranges. The normal male and female T1- and T2-mapping values were significantly different by sex, after adjusting for age and heart rate. Conclusion Using 15 healthy volunteers who are not sex specific to establish a normal range resulted in a typical misclassification of up to 36% of healthy females and 37% of healthy males as having abnormal T1 values and up to 16% of healthy females and 12% of healthy males as having abnormal T2 values. This paper highlights the potential adverse impact on diagnostic accuracy that can occur when local normal ranges contain insufficient numbers of both sexes. Sex-specific reference ranges should thus be routinely adopted in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Toward Replacing Late Gadolinium Enhancement With Artificial Intelligence Virtual Native Enhancement for Gadolinium-Free Cardiovascular Magnetic Resonance Tissue Characterization in Hypertrophic Cardiomyopathy

Author

Zhang, Qiang, Burrage, Matthew K., Lukaschuk, Elena, Shanmuganathan, Mayooran, Popescu, Iulia A., Nikolaidou, Chrysovalantou, Mills, Rebecca, Werys, Konrad, Hann, Evan, Barutcu, Ahmet, Polat, Suleyman D., Salerno, Michael, Jerosch-Herold, Michael, Kwong, Raymond Y., Watkins, Hugh C., Kramer, Christopher M., Neubauer, Stefan, Ferreira, Vanessa M., and Piechnik, Stefan K.

Published
2021
Full Text
View/download PDF

30. Cardiovascular magnetic resonance for evaluation of cardiac involvement in COVID-19: recommendations by the Society for Cardiovascular Magnetic Resonance

Author

Ferreira, Vanessa M. (author), Plein, Sven (author), Wong, Timothy C. (author), Tao, Q. (author), Raisi-Estabragh, Zahra (author), Jain, Supriya S. (author), Han, Yuchi (author), Ojha, Vineeta (author), Kim, Jiwon (author), Ferreira, Vanessa M. (author), Plein, Sven (author), Wong, Timothy C. (author), Tao, Q. (author), Raisi-Estabragh, Zahra (author), Jain, Supriya S. (author), Han, Yuchi (author), Ojha, Vineeta (author), and Kim, Jiwon (author)

Abstract

Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic that has affected nearly 600 million people to date across the world. While COVID-19 is primarily a respiratory illness, cardiac injury is also known to occur. Cardiovascular magnetic resonance (CMR) imaging is uniquely capable of characterizing myocardial tissue properties in-vivo, enabling insights into the pattern and degree of cardiac injury. The reported prevalence of myocardial involvement identified by CMR in the context of COVID-19 infection among previously hospitalized patients ranges from 26 to 60%. Variations in the reported prevalence of myocardial involvement may result from differing patient populations (e.g. differences in severity of illness) and the varying intervals between acute infection and CMR evaluation. Standardized methodologies in image acquisition, analysis, interpretation, and reporting of CMR abnormalities across would likely improve concordance between studies. This consensus document by the Society for Cardiovascular Magnetic Resonance (SCMR) provides recommendations on CMR imaging and reporting metrics towards the goal of improved standardization and uniform data acquisition and analytic approaches when performing CMR in patients with COVID-19 infection., ImPhys/Tao group

Published
2023
Full Text
View/download PDF

31. Women physicians in cardiovascular magnetic resonance: Past, present, and future

Author

Sierra-Galan, Lilia M., primary, Aggarwal, Niti R., additional, Stojanovska, Jadranka, additional, Raman, Subha V., additional, Han, Yuchi, additional, Ferreira, Vanessa M., additional, Thomas, Katharine, additional, Seiberlich, Nicole, additional, Parwani, Purvi, additional, Bucciarelli-Ducci, Chiara, additional, Baldassarre, Lauren A., additional, Mavrogeni, Sophie, additional, Ordovas, Karen, additional, Schulz-Menger, Jeanette, additional, and Bandettini, W. Patricia, additional

Published
2023
Full Text
View/download PDF

36. Neuropeptide‐Y Levels in ST‐Segment–Elevation Myocardial Infarction: Relationship With Coronary Microvascular Function, Heart Failure, and Mortality

Author

Gibbs, Thomas, primary, Tapoulal, Nidi, additional, Shanmuganathan, Mayooran, additional, Burrage, Matthew K., additional, Borlotti, Alessandra, additional, Banning, Adrian P., additional, Choudhury, Robin P., additional, Neubauer, Stefan, additional, Kharbanda, Rajesh K., additional, Ferreira, Vanessa M., additional, Channon, Keith M., additional, Herring, Neil, additional, De Maria, Giovanni Luigi, additional, Dawkins, Sam, additional, Lucking, Andrew, additional, and Langrish, Jeremy P., additional

Published
2022
Full Text
View/download PDF

37. Cardiovascular Magnetic Resonance for Patients With COVID-19

Author

Petersen, Steffen E. (author), Friedrich, Matthias G. (author), Leiner, Tim (author), Elias, Matthew D. (author), Ferreira, Vanessa M. (author), Fenski, Maximilian (author), Flamm, Scott D. (author), Fogel, Mark (author), Tao, Q. (author), Petersen, Steffen E. (author), Friedrich, Matthias G. (author), Leiner, Tim (author), Elias, Matthew D. (author), Ferreira, Vanessa M. (author), Fenski, Maximilian (author), Flamm, Scott D. (author), Fogel, Mark (author), and Tao, Q. (author)

Abstract

COVID-19 is associated with myocardial injury caused by ischemia, inflammation, or myocarditis. Cardiovascular magnetic resonance (CMR) is the noninvasive reference standard for cardiac function, structure, and tissue composition. CMR is a potentially valuable diagnostic tool in patients with COVID-19 presenting with myocardial injury and evidence of cardiac dysfunction. Although COVID-19–related myocarditis is likely infrequent, COVID-19–related cardiovascular histopathology findings have been reported in up to 48% of patients, raising the concern for long-term myocardial injury. Studies to date report CMR abnormalities in 26% to 60% of hospitalized patients who have recovered from COVID-19, including functional impairment, myocardial tissue abnormalities, late gadolinium enhancement, or pericardial abnormalities. In athletes post–COVID-19, CMR has detected myocarditis-like abnormalities. In children, multisystem inflammatory syndrome may occur 2 to 6 weeks after infection; associated myocarditis and coronary artery aneurysms are evaluable by CMR. At this time, our understanding of COVID-19–related cardiovascular involvement is incomplete, and multiple studies are planned to evaluate patients with COVID-19 using CMR. In this review, we summarize existing studies of CMR for patients with COVID-19 and present ongoing research. We also provide recommendations for clinical use of CMR for patients with acute symptoms or who are recovering from COVID-19., Green Open Access added to TU Delft Institutional Repository 'You share, we take care!' - Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public., ImPhys/Medical Imaging

Published
2022
Full Text
View/download PDF

38. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)

Author

Messroghli, Daniel R., Moon, James C., Ferreira, Vanessa M., Grosse-Wortmann, Lars, He, Taigang, Kellman, Peter, Mascherbauer, Julia, Nezafat, Reza, Salerno, Michael, Schelbert, Erik B., Taylor, Andrew J., Thompson, Richard, Ugander, Martin, van Heeswijk, Ruud B., and Friedrich, Matthias G.

Published
2017
Full Text
View/download PDF

40. Artificial Intelligence for Contrast-Free MRI: Scar Assessment in Myocardial Infarction Using Deep Learning-Based Virtual Native Enhancement.

Author

Zhang, Qiang, Burrage, Matthew K., Shanmuganathan, Mayooran, Gonzales, Ricardo A., Lukaschuk, Elena, Thomas, Katharine E., Mills, Rebecca, Leal Pelado, Joana, Nikolaidou, Chrysovalantou, Popescu, Iulia A., Lee, Yung P., Zhang, Xinheng, Dharmakumar, Rohan, Myerson, Saul G., Rider, Oliver, Channon, Keith M., Neubauer, Stefan, Piechnik, Stefan K., Ferreira, Vanessa M., and Oxford Acute Myocardial Infarction (OxAMI) Study

Published
2022
Full Text
View/download PDF

41. The impact of atrial fibrillation and stroke risk factors on left atrial blood flow characteristics

Author

Spartera, Marco, primary, Stracquadanio, Antonio, additional, Pessoa-Amorim, Guilherme, additional, Von Ende, Adam, additional, Fletcher, Alison, additional, Manley, Peter, additional, Ferreira, Vanessa M, additional, Hess, Aaron T, additional, Hopewell, Jemma C, additional, Neubauer, Stefan, additional, Wijesurendra, Rohan S, additional, and Casadei, Barbara, additional

Published
2021
Full Text
View/download PDF

44. Markers of Myocardial Damage Predict Mortality in Patients With Aortic Stenosis.

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Kwak, Soongu, Everett, Russell J, Treibel, Thomas A, Yang, Seokhun, Hwang, Doyeon, Ko, Taehoon, Williams, Michelle C, Bing, Rong, Singh, Trisha, Joshi, Shruti, Lee, Heesun, Lee, Whal, Kim, Yong-Jin, Chin, Calvin W L, Fukui, Miho, Al Musa, Tarique, Rigolli, Marzia, Singh, Anvesha, Tastet, Lionel, Dobson, Laura E, Wiesemann, Stephanie, Ferreira, Vanessa M, Captur, Gabriella, Lee, Sahmin, Schulz-Menger, Jeanette, Schelbert, Erik B, Clavel, Marie-Annick, Park, Sung-Ji, Rheude, Tobias, Hadamitzky, Martin, Gerber, Bernhard, Newby, David E, Myerson, Saul G, Pibarot, Phillipe, Cavalcante, João L, McCann, Gerry P, Greenwood, John P, Moon, James C, Dweck, Marc R, Lee, Seung-Pyo, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Kwak, Soongu, Everett, Russell J, Treibel, Thomas A, Yang, Seokhun, Hwang, Doyeon, Ko, Taehoon, Williams, Michelle C, Bing, Rong, Singh, Trisha, Joshi, Shruti, Lee, Heesun, Lee, Whal, Kim, Yong-Jin, Chin, Calvin W L, Fukui, Miho, Al Musa, Tarique, Rigolli, Marzia, Singh, Anvesha, Tastet, Lionel, Dobson, Laura E, Wiesemann, Stephanie, Ferreira, Vanessa M, Captur, Gabriella, Lee, Sahmin, Schulz-Menger, Jeanette, Schelbert, Erik B, Clavel, Marie-Annick, Park, Sung-Ji, Rheude, Tobias, Hadamitzky, Martin, Gerber, Bernhard, Newby, David E, Myerson, Saul G, Pibarot, Phillipe, Cavalcante, João L, McCann, Gerry P, Greenwood, John P, Moon, James C, Dweck, Marc R, and Lee, Seung-Pyo

Abstract

Cardiovascular magnetic resonance (CMR) is increasingly used for risk stratification in aortic stenosis (AS). However, the relative prognostic power of CMR markers and their respective thresholds remains undefined. Using machine learning, the study aimed to identify prognostically important CMR markers in AS and their thresholds of mortality. Patients with severe AS undergoing AVR (n = 440, derivation; n = 359, validation cohort) were prospectively enrolled across 13 international sites (median 3.8 years' follow-up). CMR was performed shortly before surgical or transcatheter AVR. A random survival forest model was built using 29 variables (13 CMR) with post-AVR death as the outcome. There were 52 deaths in the derivation cohort and 51 deaths in the validation cohort. The 4 most predictive CMR markers were extracellular volume fraction, late gadolinium enhancement, indexed left ventricular end-diastolic volume (LVEDVi), and right ventricular ejection fraction. Across the whole cohort and in asymptomatic patients, risk-adjusted predicted mortality increased strongly once extracellular volume fraction exceeded 27%, while late gadolinium enhancement >2% showed persistent high risk. Increased mortality was also observed with both large (LVEDVi >80 mL/m) and small (LVEDVi ≤55 mL/m) ventricles, and with high (>80%) and low (≤50%) right ventricular ejection fraction. The predictability was improved when these 4 markers were added to clinical factors (3-year C-index: 0.778 vs 0.739). The prognostic thresholds and risk stratification by CMR variables were reproduced in the validation cohort. Machine learning identified myocardial fibrosis and biventricular remodeling markers as the top predictors of survival in AS and highlighted their nonlinear association with mortality. These markers may have potential in optimizing the decision of AVR.

Published
2021

45. Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients:the CONDI-2/ERIC-PPCI CMR substudy

Author

Francis, Rohin, Chong, Jun, Ramlall, Manish, Bucciarelli-Ducci, Chiara, Clayton, Tim, Dodd, Matthew, Engstrøm, Thomas, Evans, Richard, Ferreira, Vanessa M., Fontana, Marianna, Greenwood, John P., Kharbanda, Rajesh K., Kim, Won Yong, Kotecha, Tushar, Lønborg, Jacob T., Mathur, Anthony, Møller, Ulla Kristine, Moon, James, Perkins, Alexander, Rakhit, Roby D., Yellon, Derek M., Bøtker, Hans Erik, Bulluck, Heerajnarain, Hausenloy, Derek J., Francis, Rohin, Chong, Jun, Ramlall, Manish, Bucciarelli-Ducci, Chiara, Clayton, Tim, Dodd, Matthew, Engstrøm, Thomas, Evans, Richard, Ferreira, Vanessa M., Fontana, Marianna, Greenwood, John P., Kharbanda, Rajesh K., Kim, Won Yong, Kotecha, Tushar, Lønborg, Jacob T., Mathur, Anthony, Møller, Ulla Kristine, Moon, James, Perkins, Alexander, Rakhit, Roby D., Yellon, Derek M., Bøtker, Hans Erik, Bulluck, Heerajnarain, and Hausenloy, Derek J.

Abstract

The effect of limb remote ischaemic conditioning (RIC) on myocardial infarct (MI) size and left ventricular ejection fraction (LVEF) was investigated in a pre-planned cardiovascular magnetic resonance (CMR) substudy of the CONDI-2/ERIC-PPCI trial. This single-blind multi-centre trial (7 sites in UK and Denmark) included 169 ST-segment elevation myocardial infarction (STEMI) patients who were already randomised to either control (n = 89) or limb RIC (n = 80) (4 × 5 min cycles of arm cuff inflations/deflations) prior to primary percutaneous coronary intervention. CMR was performed acutely and at 6 months. The primary endpoint was MI size on the 6 month CMR scan, expressed as median and interquartile range. In 110 patients with 6-month CMR data, limb RIC did not reduce MI size [RIC: 13.0 (5.1–17.1)% of LV mass; control: 11.1 (7.0–17.8)% of LV mass, P = 0.39], or LVEF, when compared to control. In 162 patients with acute CMR data, limb RIC had no effect on acute MI size, microvascular obstruction and LVEF when compared to control. In a subgroup of anterior STEMI patients, RIC was associated with lower incidence of microvascular obstruction and higher LVEF on the acute scan when compared with control, but this was not associated with an improvement in LVEF at 6 months. In summary, in this pre-planned CMR substudy of the CONDI-2/ERIC-PPCI trial, there was no evidence that limb RIC reduced MI size or improved LVEF at 6 months by CMR, findings which are consistent with the neutral effects of limb RIC on clinical outcomes reported in the main CONDI-2/ERIC-PPCI trial.

Published
2021

46. Quality assurance of quantitative cardiac T1-mapping in multicenter clinical trials – A T1 phantom program from the hypertrophic cardiomyopathy registry (HCMR) study

Author

Zhang, Qiang, Werys, Konrad, Popescu, Iulia A., Biasiolli, Luca, Ntusi, Ntobeko A.B., Desai, Milind, Zimmerman, Stefan L., Shah, Dipan J., Autry, Kyle, Kim, Bette, Kim, Han W., Jenista, Elizabeth R., Huber, Steffen, White, James A., McCann, Gerry P., Mohiddin, Saidi A., Boubertakh, Redha, Chiribiri, Amedeo, Newby, David, Prasad, Sanjay, Radjenovic, Aleksandra, Dawson, Dana, Schulz-Menger, Jeanette, Mahrholdt, Heiko, Carbone, Iacopo, Rimoldi, Ornella, Colagrande, Stefano, Calistri, Linda, Michels, Michelle, Hofman, Mark B.M., Anderson, Lisa, Broberg, Craig, Andrew, Flett, Sanz, Javier, Bucciarelli-Ducci, Chiara, Chow, Kelvin, Higgins, David, Broadbent, David A., Semple, Scott, Hafyane, Tarik, Wormleighton, Joanne, Salerno, Michael, He, Taigang, Plein, Sven, Kwong, Raymond Y., Jerosch-Herold, Michael, Kramer, Christopher M., Neubauer, Stefan, Ferreira, Vanessa M., Piechnik, Stefan K., Zhang, Qiang, Werys, Konrad, Popescu, Iulia A., Biasiolli, Luca, Ntusi, Ntobeko A.B., Desai, Milind, Zimmerman, Stefan L., Shah, Dipan J., Autry, Kyle, Kim, Bette, Kim, Han W., Jenista, Elizabeth R., Huber, Steffen, White, James A., McCann, Gerry P., Mohiddin, Saidi A., Boubertakh, Redha, Chiribiri, Amedeo, Newby, David, Prasad, Sanjay, Radjenovic, Aleksandra, Dawson, Dana, Schulz-Menger, Jeanette, Mahrholdt, Heiko, Carbone, Iacopo, Rimoldi, Ornella, Colagrande, Stefano, Calistri, Linda, Michels, Michelle, Hofman, Mark B.M., Anderson, Lisa, Broberg, Craig, Andrew, Flett, Sanz, Javier, Bucciarelli-Ducci, Chiara, Chow, Kelvin, Higgins, David, Broadbent, David A., Semple, Scott, Hafyane, Tarik, Wormleighton, Joanne, Salerno, Michael, He, Taigang, Plein, Sven, Kwong, Raymond Y., Jerosch-Herold, Michael, Kramer, Christopher M., Neubauer, Stefan, Ferreira, Vanessa M., and Piechnik, Stefan K.

Abstract

Background: Quantitative cardiovascular magnetic resonance T1-mapping is increasingly used for myocardial tissue characterization. However, the lack of standardization limits direct comparability between centers and wider roll-out for clinical use or trials. Purpose: To develop a quality assurance (QA) program assuring standardized T1 measurements for clinical use. Methods: MR phantoms manufactured in 2013 were distributed, including ShMOLLI T1-mapping and reference T1 and T2 protocols. We first studied the T1 and T2 dependency on temperature and phantom aging using phantom datasets from a single site over 4 years. Based on this, we developed a multiparametric QA model, which was then applied to 78 scans from 28 other multi-national sites. Results: T1 temperature sensitivity followed a second-order polynomial to baseline T1 values (R2 > 0.996). Some phantoms showed aging effects, where T1 drifted up to 49% over 40 months. The correlation model based on reference T1 and T2, developed on 1004 dedicated phantom scans, predicted ShMOLLI-T1 with high consistency (coefficient of variation 1.54%), and was robust to temperature variations and phantom aging. Using the 95% confidence interval of the correlation model residuals as the tolerance range, we analyzed 390 ShMOLLI T1-maps and confirmed accurate sequence deployment in 90%(70/78) of QA scans across 28 multiple centers, and categorized the rest with specific remedial actions. Conclusions: The proposed phantom QA for T1-mapping can assure correct method implementation and protocol adherence, and is robust to temperature variation and phantom aging. This QA program circumvents the need of frequent phantom replacements, and can be readily deployed in multicenter trials.

Published
2021

47. Rationale and design of the Medical Research Council precision medicine with Zibotentan in microvascular angina (PRIZE) trial

Author

Morrow, Andrew J., Ford, Thomas J., Mangion, Kenneth, Kotecha, Tushar, Rakhit, Roby, Galasko, Gavin, Hoole, Stephen, Davenport, Anthony, Kharbanda, Rajesh, Ferreira, Vanessa M., Shanmuganathan, Mayooran, Chiribiri, Amedeo, Perera, Divaka, Rahman, Haseeb, Arnold, Jayanth R., Greenwood, John P., Fisher, Michael, Husmeier, Dirk, Hill, Nicholas A., Luo, Xiaoyu, Williams, Nicola, Miller, Laura, Dempster, Jill, Macfarlane, Peter W., Welsh, Paul, Sattar, Naveed, Whittaker, Andrew, McConnachie, Alex, Padmanabhan, Sandosh, and Berry, Colin

Abstract

Background: \ud Microvascular angina is caused by cardiac small vessel disease and dysregulation of the endothelin system is implicated. The minor G allele of the non-coding single nucleotide polymorphism (SNP) rs9349379 enhances expression of the endothelin 1 gene in human vascular cells, increasing circulating concentrations of ET-1. The prevalence of this allele is higher in patients with ischemic heart disease. Zibotentan is a potent, selective inhibitor of the ETA receptor. We have identified zibotentan as a potential disease-modifying therapy for patients with microvascular angina.\ud \ud Methods: \ud We will assess the efficacy and safety of adjunctive treatment with oral zibotentan (10 mg daily) in patients with microvascular angina and assess whether rs9349379 (minor G allele; population prevalence ~36%) acts as a theragnostic biomarker of the response to treatment with zibotentan.\ud \ud The Precision medicine with Zibotentan in microvascular angina (PRIZE) trial is a prospective, randomized, double-blind, placebo-controlled, sequential cross-over trial. The study population will be enriched to ensure a G-allele frequency of 50% for the rs9349379 SNP. The participants will receive a single-blind placebo run-in followed by treatment with either 10 mg of zibotentan daily for 12 weeks then placebo for 12 weeks, or vice versa, in random order. The primary outcome is treadmill exercise duration using the Bruce protocol. The primary analysis will assess the within-subject difference in exercise duration following treatment with zibotentan versus placebo.\ud \ud Conclusion: \ud PRIZE invokes precision medicine in microvascular angina. Should our hypotheses be confirmed, this developmental trial will inform the rationale and design for undertaking a larger multicenter trial.

Published
2020

48. EXPERIMENTAL KIDNEY INJURY MECHANISMS

Author

Oliveira-Salles, Elizabeth B., Maquigussa, Edgar, Semedo, Patricia, Pereira, Luciana G., Ferreira, Vanessa M., Camara, Niels O., Bergamaschi, Cassia T., Campos, Ruy R., and Boim, Mirian A.

Published
2014

50. Extracellular myocardial volume in patients with aortic stenosis

Author

Everett, Russell J., Treibel, Thomas Alexander, Fukui, Miho, Lee, Heesun, Rigolli, Marzia, Singh, Anvesha, Bijsterveld, Petra, Tastet, Lionel, Musa, Tarique Al, Dobson, Laura, Chin, Calvin, Captur, Gabriella, Sang, Yong Om, Wiesemann, Stéphanie, Ferreira, Vanessa M., Piechnik, Stefan K., Schulz-Menger, Jeanette, Schelbert, Erik, Clavel, Marie-Annick, Newby, David E., Myerson, Saul G., Pibarot, Philippe, Lee, Sahmin, Cavalcante, João L., Lee, Seung-Pyo, McCann, Gerry P., Greenwood, John P., Moon, James, Dweck, Marc, Everett, Russell J., Treibel, Thomas Alexander, Fukui, Miho, Lee, Heesun, Rigolli, Marzia, Singh, Anvesha, Bijsterveld, Petra, Tastet, Lionel, Musa, Tarique Al, Dobson, Laura, Chin, Calvin, Captur, Gabriella, Sang, Yong Om, Wiesemann, Stéphanie, Ferreira, Vanessa M., Piechnik, Stefan K., Schulz-Menger, Jeanette, Schelbert, Erik, Clavel, Marie-Annick, Newby, David E., Myerson, Saul G., Pibarot, Philippe, Lee, Sahmin, Cavalcante, João L., Lee, Seung-Pyo, McCann, Gerry P., Greenwood, John P., Moon, James, and Dweck, Marc

Abstract

Background : Myocardial fibrosis is a key mechanism of left ventricular decompensation in aortic stenosis and can be quantified using cardiovascular magnetic resonance (CMR) measures such as extracellular volume fraction (ECV%). Outcomes following aortic valve intervention may be linked to the presence and extent of myocardial fibrosis. Objectives : This study sought to determine associations between ECV% and markers of left ventricular decompensation and post-intervention clinical outcomes. Methods : Patients with severe aortic stenosis underwent CMR, including ECV% quantification using modified Look-Locker inversion recovery–based T1 mapping and late gadolinium enhancement before aortic valve intervention. A central core laboratory quantified CMR parameters. Results : Four-hundred forty patients (age 70 ± 10 years, 59% male) from 10 international centers underwent CMR a median of 15 days (IQR: 4 to 58 days) before aortic valve intervention. ECV% did not vary by scanner manufacturer, magnetic field strength, or T1 mapping sequence (all p > 0.20). ECV% correlated with markers of left ventricular decompensation including left ventricular mass, left atrial volume, New York Heart Association functional class III/IV, late gadolinium enhancement, and lower left ventricular ejection fraction (p < 0.05 for all), the latter 2 associations being independent of all other clinical variables (p = 0.035 and p < 0.001). After a median of 3.8 years (IQR: 2.8 to 4.6 years) of follow-up, 52 patients had died, 14 from adjudicated cardiovascular causes. A progressive increase in all-cause mortality was seen across tertiles of ECV% (17.3, 31.6, and 52.7 deaths per 1,000 patient-years; log-rank test; p = 0.009). Not only was ECV% associated with cardiovascular mortality (p = 0.003), but it was also independently associated with all-cause mortality following adjustment for age, sex, ejection fraction, and late gadolinium enhancement (hazard ratio per percent increase in ECV%: 1.10; 95% c

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results